# CardiAQ Valve Technologies

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cardiaq-valve-technologies

- Industry: Healthcare IT
- Headquarters: Irvine, US
- Website: www.cardiaq.com
- Total disclosed funding: $38M
- Latest round: Series B (Nov 29, 2012)
- Investors on record: 4

## About

CardiAQ Valve Technologies is dedicated to transforming cardiac care through its innovative heart valve solutions, enhancing treatment options for patients with valvular heart disease.CardiAQ Valve Technologies specializes in developing transcatheter heart valve technologies. Founded in 2007 in Irvine, US, it has undergone significant funding activities, culminating in a TRADE SALE to Edwards Lifesciences Corporation in July 2015 for USD 400.00 mn, which represents the total amount raised. The company has completed five deals since its inception.CardiAQ Valve Technologies focuses on advanced heart valve technologies, particularly in the field of transcatheter heart valve replacement systems. Their products are designed to provide less invasive treatment options for patients suffering from valvular heart disease, improving recovery times and patient outcomes by facilitating more efficient cardiac procedures.CardiAQ generates revenue primarily through the sales of its innovative medical devices to healthcare providers, hospitals, and cardiology specialists. The company maintains strong B2B relationships and supports its sales with clinical evidence that demonstrates the effectiveness of its heart valve technologies, ensuring ongoing partnerships in the healthcare market.Looking ahead, CardiAQ aims to expand its product offerings and increase its market reach. Following its acquisition by Edwards Lifesciences, the company plans to leverage this partnership to introduce new heart valve solutions in the upcoming years. The recent acquisition funding is expected to support these initiatives, enhancing development and distribution capabilities to penetrate new geographic markets in North America and Europe by 2025.

## Funding rounds

- Series B, Nov 29, 2012, $37M — OrbiMed Advisors, Versant Ventures, Advent Life Sciences
- Seed, May 13, 2009, $0.8M — Broadview Ventures

## Investors

- Broadview Ventures (https://capitalatlas.ai/funds/broadview-ventures) — Seed
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series B
- Advent Life Sciences (https://capitalatlas.ai/funds/advent-life-sciences) — Series B